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Abstract
Background: The development of cost-effective prophylactic strategies to prevent leishmaniasis has become a high-priority.
The present study has used the phage display technology to identify new immunogens, which were evaluated as vaccines
in the murine model of visceral leishmaniasis (VL). Epitope-based immunogens, represented by phage-fused peptides that
mimic Leishmania infantum antigens, were selected according to their affinity to antibodies from asymptomatic and
symptomatic VL dogs’ sera.
Methodology/Main Findings: Twenty phage clones were selected after three selection cycles, and were evaluated by
means of in vitro assays of the immune stimulation of spleen cells derived from naive and chronically infected with L.
infantum BALB/c mice. Clones that were able to induce specific Th1 immune response, represented by high levels of IFN-c
and low levels of IL-4 were selected, and based on their selectivity and specificity, two clones, namely B10 and C01, were
further employed in the vaccination protocols. BALB/c mice vaccinated with clones plus saponin showed both a high and
specific production of IFN-c, IL-12, and GM-CSF after in vitro stimulation with individual clones or L. infantum extracts.
Additionally, these animals, when compared to control groups (saline, saponin, wild-type phage plus saponin, or non-
relevant phage clone plus saponin), showed significant reductions in the parasite burden in the liver, spleen, bone marrow,
and paws’ draining lymph nodes. Protection was associated with an IL-12-dependent production of IFN-c, mainly by CD8+ T
cells, against parasite proteins. These animals also presented decreased parasite-mediated IL-4 and IL-10 responses, and
increased levels of parasite-specific IgG2a antibodies.
Conclusions/Significance: This study describes two phage clones that mimic L. infantum antigens, which were directly used
as immunogens in vaccines and presented Th1-type immune responses, and that significantly reduced the parasite burden.
This is the first study that describes phage-displayed peptides as successful immunogens in vaccine formulations against VL.
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Introduction
Leishmaniasis is a disease with a wide spectrum of clinical
manifestations caused by different species of protozoa belonging to
the Leishmania genus [1]. The disease presents a high morbidity
and mortality throughout the world, where 350 million people in
98 countries are at risk of contracting the infection. Moreover,
approximately 1.0 to 1.5 million cases of cutaneous leishmaniasis
(CL), and 200,000 to 500,000 cases of visceral leishmaniasis (VL),
are registered annually [2,3]. Canine visceral leishmaniasis (CVL)
due to Leishmania infantum is a major global zoonosis that is
potentially fatal to dogs [4]. This disease can be found in Southern
Europe, Africa, Asia, and Central and South America; and is
endemic in approximately 70 countries worldwide [5]. CVL is
expanding its geographic distribution throughout the Western
hemisphere, where it now occurs from northern Argentina to the
United States [6], even reaching as far as provinces of southern
Canada [7]. This disease is also an important concern in non-
endemic countries, where imported sick or infected dogs constitute
a veterinary and public health problem [6,7].
The treatment of leishmaniasis is still based on the use of the
parenteral administration of pentavalent antimonial compounds;
however, several side effects reported by patients, and increased
parasite resistance have produced serious problems [8,9]. There-
fore, the development of new strategies to prevent leishmaniasis
has become a high priority [10].
The evidence of life-long immunity has inspired the develop-
ment of vaccination protocols against the disease, but few have
progressed beyond the experimental stage. Some studies have
demonstrated that the Type-1 cells mediated immunity is
important to a protective response against CL [11–15]. In
addition, Th1 cells response has also been correlated with the
protection against VL [16]. In this context, the protective
immunity in murine VL primarily depends on an IL-12-driven
Th1 cells response, leading to an IFN-c and IL-2 production.
Substantial up regulation of inducible NO synthase by IFN-c
generates NO from splenic and liver cells, thereby controlling
parasite replication in these organs [16,17]. By contrast, TGF-b,
IL-10, and IL-13 represent major disease promoting cytokines, in
turn leading to the suppression of the Th1 response [18]. Low
levels of IL-4 can enhance vaccine-induced protection by
indirectly increasing IFN-c production by Th1 cells [19]. Thus,
antigens that are capable of stimulating the development of a Th1
immune response in murine models, primed by the production of
cytokines, such as IFN-c and IL-12, in in vitro spleen cell cultures,
could be considered promising vaccine candidates for use against
Leishmania infection [20,21].
One interesting approach toward the discovery of new antigens
with biotechnological applications has been based on phage
display technology [22]. This technique is based on DNA
recombination, resulting in the expression of foreign peptide
variants on the outer surface of phages. Using an in vitro selection
process, based on binding affinity and so-called bio-panning cycles,
peptides exposed in the selected phage clones are analyzed by
DNA sequencing and identified [23–25]. Phage display has been
used to identify mimotopes (peptides that mimic linear, discontin-
uous, and even non-peptide epitopes [26]) to be applied in the
diagnoses of diseases, including malaria [27–29], leishmaniasis
[30], toxoplasmosis [31,32], and Chagas disease [33]; as well as
employed as vaccine candidates in the cysticercosis [34],
trichinellosis [35], and Alzheimers disease [36].
In the present study, phage display was used to identify
mimotopes expressed on a foreign surface of phages, to be applied
as vaccine candidates against L. infantum. Clones from a phage
library were selected by antibodies present in sera samples of dogs
with asymptomatic and symptomatic VL, and they were used for
the in vitro immune stimulation of spleen cells obtained from naive
or chronically infected with L. infantum BALB/c mice; in an
attempt to select those able to stimulate a higher production of
IFN-c and lower levels of IL-4. Two phage clones presenting the
best results of specificity and selectivity were selected and
evaluated in vaccination experiments in BALB/c mice. Both
clones, namely B10 and C01, were able to induce a Th1 immune
response in the vaccinated mice, and were protective against L.
infantum infection. In this context, these two antigens, identified
by a non-described study using phage display and leishmaniasis;
could be considered candidates to compose an effective vaccine
against VL.
Materials and Methods
Ethics Statement
Experiments were performed in compliance with the National
Guidelines, as set forth by the Institutional Animal Care (Law
number 11.794, 2008), and the Committee on the Ethical
Handling of Research Animals from the Federal University of
Minas Gerais (UFMG), who approved this study under protocol
number 043/2011. In addition, the owners of the domestic dogs
(Canis familiaris) gave permission for their animals to be used in
this study.
Mice and parasites
Female BALB/c mice (8 weeks of age) were obtained from the
breeding facilities of the Department of Biochemistry and
Immunology, Institute of Biological Sciences (ICB), UFMG; and
were maintained under specific pathogen-free conditions. Exper-
iments were carried out using the L. infantum (MOM/BR/1970/
BH46) strain. Parasites were grown at 24uC in Schneider’s
medium (Sigma-Aldrich, St. Louis, MO, USA), supplemented
with 10% heat-inactivated fetal bovine serum (FBS; Sigma-
Aldrich), 20 mM L-glutamine, 200 U/mL penicillin, and
100 mg/mL streptomycin, pH 7.4. The soluble Leishmania
antigenic (SLA) extract was prepared from stationary promasti-
gotes of L. infantum, after few passages in liquid culture, as
described [11]. Briefly, 26108 promastigotes per mL, in a volume
of 5 mL, were washed 3 times in 5 mL of cold sterile phosphate-
buffered saline (PBS). After five cycles of freezing and thawing, the
suspension was centrifuged at 8,0006g for 20 min at 4uC, and the
supernatant containing SLA was collected in 500 mL aliquots and
stored at 270uC, until use. The protein concentration was
estimated by Bradford method [37].
Sera samples
The sample size used in this study consisted of 60 domestic dogs,
made up of males and females of different breeds and ages,
collected from an endemic area of Belo Horizonte, Minas Gerais,
Brazil. Sera of CVL were selected on the basis of two serological
tests (IFAT [IFAT-LVC Bio-Manguinhos kit] and ELISA [EIE-
LVC Bio-Manguinhos kit], both from Bio-Manguinhos, Fiocruz,
Brazil) for Leishmania spp. Dogs with an IFAT titre ,1/40 or
ELISA reactivity below the cut-off value indicated by the
manufacturer were considered to be seronegative. Animals with
an IFAT titre. 1/40 and an ELISA value over the cut-off were
considered to be seropositive. Thus, symptomatic dogs (n = 20)
were those positive by IFAT and ELISA, but also with positive
parasitological results by PCR-RFLP (restriction fragment length
polymorphism), as well as presenting more than three clinical
symptoms (weight loss, alopecia, adenopathy, onychogryposis,
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hepatomegaly, conjunctivitis; and exfoliative dermatitis on the
nose, tail, and ear tips). Asymptomatic dogs (n = 20) presented
positive serological (IFAT and ELISA) and parasitological (PCR-
RFLP) results, but they did not present any clinical signals or
symptoms of leishmaniasis. Healthy dogs (n = 20) were selected
from an endemic area of Belo Horizonte, but they presented
negative serological and parasitological results, as well as were free
of any clinical signs or symptoms of leishmaniasis.
Purification of antibodies by coupling in protein G
microspheres
In order to obtain microspheres incorporated with IgG
molecules derived from different sera groups, a purification was
performed using the coupling to magnetic microspheres (beads),
conjugated to protein G (Dynabeads, Invitrogen). For this, 26109
microspheres were prepared by washing 3 times with 1 mL of
0.1 M MES buffer pH 5.0, been separately added to them:
375 mL of a pool of sera of healthy dogs (n = 20), 195 mL of a pool
of sera of asymptomatic CVL (n = 20), or 300 mL of a pool of sera
of symptomatic CVL (n = 20). After this, an incubation of 40 min
was performed with each pool of sera and microspheres, under
constant stirring and at room temperature. The microspheres
coupled with each antibodies group were then washed 3 times
using 1 mL of 0.1 M MES buffer pH 5.0, in order to remove the
non-adhered molecules. Next, the system was washed twice with
1 mL of 0.2 M triethanolamine buffer pH 8.2, and resuspended in
1 mL of covalent coupling buffer (containing 20 mM dimethy
pimelimidate/HCl diluted in triethanolamine buffer) for 30 min,
under constant stirring, at room temperature. The neutralization
of unbound sites was made by incubating 1 mL of 50 mM Tris-
base pH 7.5, for 15 min at room temperature. The system (beads
plus antibodies) was washed 3 times with 1 mL TBS-T (50 mM
Tris-HCl pH 7.5, 150 mM NaCl, and 0.1% Tween 20) buffer,
blocked by addition of 2 mL of a blocking solution (5% BSA
diluted in TBS-T) for 1 h at 37uC, and resuspended in 200 mL of
TBS (50 mM Tris-HCl pH 7.5 and 150 mM NaCl) buffer. To
verify the coupling of the generated beads-IgG systems (using
healthy dogs, asymptomatic and symptomatic CVL sera), 5 mL of
them were individually incubated with an anti-dog IgG peroxidase
antibody (1:5,000 dilution), for 1 h at 37uC. After this, they were
washed 3 times with 1 mL of TBS-T, and the reaction was
revealed by adding TMB substrate, being then stopped by adding
25 mL H2SO4 2 N. The optical density was read in an ELISA
microplate spectrophotometer (Molecular Devices, Spectra Max
Plus, Canada), at 450 nm.
Bio-panning cycles
To carry out a negative selection process in the bio-panning
cycles, 161011 viral particles from a phage library containing
random seven-peptides fused to a minor coat protein of M13
filamentous phages (Ph.D.-C7C library, New England BioLabs,
USA) were diluted in 190 mL of TBS-T buffer. The mixture was
incubated for 30 min at room temperature with the microspheres
coupled to IgGs that had been purified from healthy dogs, and
then precipitated by magnetic attraction to produce a Dynal
Biotech support (12020). The supernatant containing the clones
that were not adhered to the IgGs was recovered and transferred
to a new tube, been this procedure repeated for three times. After
this, a positive selection process was performed. For this, the
supernatant containing the previously recovered phage clones
were transferred to a new tube containing the microspheres
coupled to IgGs purified from asymptomatic CVL, and incubation
occurred for 30 min at room temperature. After, the supernatant
was removed, and the remained bound phages to the IgGs were
washed 10 times with 1 mL of TBS-T, and eluted in 500 mL of
0.2 M glycine buffer, pH 2.0. Next, 75 mL of 1 M Tris-base
pH 9.0 was added to neutralize the acid pH. Subsequently, the
recovered phage clones were transferred to a new tube containing
the IgGs purified from asymptomatic CVL, and the process was
repeated for three times. After this, the recovered phage clones
were transferred to a new tube containing the IgGs that had been
purified from symptomatic CVL, and the process was also
repeated for three times, when the selected clones reactive to
IgGs from asymptomatic and symptomatic sera of CVL were then
recovered and titrated.
Titration of phage clones
Phage clones were diluted 1021 to 10211 in 500 mL of sterile
TBS buffer, mixed with an Escherichia coli culture (OD600nm ,
0.5), and plated on LB agar plates containing 1 mL of a IPTG/X-
gal solution (composed by 200 mg/mL isopropyl b-D-1-thioga-
lactopyranoside and 20 mg/mL 5-bromo-4-chloro-3-indolyl-b-D-
galactoside, diluted in dimethyl sulfoxide PA). Colonies were
individually quantified, and the titration was performed for each
bio-panning cycle. After the 3rd round of positive selection using
IgGs from CVL sera, 96 colonies selected from the plate were
added in 200 mL of LB (Luria Bertani) medium in a sterile culture
plate (BD Falcon TM clear, 96-well microtest TM plate), then the
plate was sealed and incubated for 5 h, under constant stirring, at
37uC. After incubation, the plate was centrifuged for 20 min by
2,2506g, and the supernatant was transferred to a new plate,
where a PEG/NaCl solution (20% PEG 8,000 and 2.5 M NaCl)
was added (1/6 of the total volume of supernatant), and the plate
was incubated for 16 h at 4uC. After, the plate was centrifuged for
1 h, the supernatant was removed, and the pellet was resuspended
in 500 mL of a solution composed by 10 mM Tris-HCl pH 8.0,
1 mM EDTA, and 4 M NaI. The plate was shaken vigorously for
5 min, when 250 mL of a 70% ethanol solution was added. After
having been incubated for 10 min, the plate was centrifuged
(2,2506g at 4uC for 10 min), and the supernatant was discarded.
The pellet containing the DNA of interest of each clone was
washed with 500 mL of 70% ethanol, and again centrifuged.
Finally, the DNA was diluted in 20 mL of ultra-pure water, and its
quality was evaluated in a 1% agarose gel, which was stained with
an ethidium bromide solution (10 mg mL21). The individual DNA
of clones was used for the sequencing and identification of target
peptides.
DNA sequencing and bioinformatics
The sequencing reaction was performed using 500 ng of DNA
for each selected phage clone, 5 pmol primer 96 gIII (59-OH CC
TCA TAG TTA GCG TAA CG-39, Biolabs), plus a pre-mix (Dye
Terminator Cycle ET Journal Kit, Amersham Biosciences).
Thirty-five cycles were performed in a thermocycler, under the
following conditions: denaturation at 95uC for 20 sec, ringing at
58uC for 15 sec, and extension at 60uC for 60 sec. Ten microliters
of the generated amplicons were precipitated with 1 mL of
ammonium acetate (1:10 ratio), added with 27.5 mL of ethanol
PA. The plate was centrifuged for 45 min to 2,4326g, when the
supernatant was discarded and 150 mL of 70% ethanol was added
to the pellet. The resuspended DNA was centrifuged for 10 min at
2,4326g, and the supernatant was discarded again. The plate was
inverted on a paper towel and, in this position, was centrifuged at
4866g for 1 min. Next, the plate was covered for 5 min, until the
complete evaporation of the remaining ethanol had been
achieved. The pellet was resuspended in dilution buffer, and the
sequencing was performed in a MegaBace 1000 automatic
sequencer (Amersham Biosciences). Peptide sequences of 20 valid
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phage clones were deduced using the Expasy server (www.expasy.
org), and analyzed with the Pepbank [38], MimoDB [39] and
SAROTUP [40] programs to identify possible false-positive
sequences.
Evaluation of the in vitro immune stimulation
BALB/c mice (n = 8) were subcutaneously infected with 16107
stationary phase promastigotes of L. infantum, and they were
monitored by 10 weeks. Liver, spleen, paws’ draining lymph nodes
(dLN), and bone marrow (BM) of the animals were collected for
parasite quantification, following a limiting-dilution technique
[11]. The parasite load was performed to confirm that the animals
were chronically infected (data not shown). After this, spleen cells
were collected, pooled and in vitro cultured in 24-well plates
(Nunc, NunclonH, Roskilde, Denmark), at 56106 cells per mL, in
duplicate. Cells were incubated in RPMI 1640 medium (Sigma-
Aldrich; non-stimulated control), or separately stimulated with
each phage clone (20 individual clones, with 161010 phages per
well), at 37uC in 5% CO2 for 48 h. The same experimental
conditions were performed using spleen cells of naive mice. Wild-
type and random non-specific phage clones were used like
controls. The IFN-c and IL-4 levels were determined in the
culture supernatants, using commercial kits (BD OptEIA,
Pharmingen, San Diego, CA, USA), according to manufacturer
instructions. Experiments were repeated twice and presented
similar results.
Immunization and challenge infection
After the in vitro immunogenicity experiments, two from 20
phage clones were selected, namely B10 and C01, based on their
polarized Th1 immune response, and were used in the in vivo
experiments. For this, BALB/c mice (n = 8, per group) were
vaccinated subcutaneously in their left hind footpad with two
selected clones or wild-type phage (161011 phages, each one),
associated with 25 mg of saponin (Quillaja saponaria bark saponin;
Sigma Aldrich), only adjuvant or received the diluent (saline).
Three doses were administered at 2-week intervals. Four weeks
after the last immunization, animals (n = 4, per group) were
euthanized for the analysis of the immune response elicited by
vaccination. At the same time, the remaining animals were
infected subcutaneously in their right hind footpad with 16107
stationary promastigotes of L. infantum, and they were follow-up
for 10 weeks. Experiments were repeated twice and presented
similar results.
Estimation of parasite load
The liver, spleen, BM and dLN were collected of the euthanized
animals for parasite quantification, using a limiting-dilution
protocol [11]. Briefly, organs were weighed and homogenized
using a glass tissue grinder in sterile PBS. Tissue debris were
removed by centrifugation at 1506g, and cells were concentrated
by centrifugation at 2,0006 g. Pellets were resuspended in 1 mL
of Schneider’s insect medium supplemented with 20% FBS. Two
hundred and twenty microliters were plated onto 96-well flat-
bottom microtiter plates (Nunc), and diluted in log-fold serial
dilutions using supplemented Schneider’s medium, to a 1021 to
10212 dilution. Each sample was plated in triplicate and read 7
days after the beginning of the culture, at 24uC. Pipette tips were
discarded after each dilution to avoid carrying adhered parasites
from one well to another. Results are expressed as the negative log
of the titer (i.e., the dilution corresponding to the last positive well)
adjusted per microgram of tissue.
Cytokine production
Splenocytes cultures and cytokine assays were performed before
infection and at 10th week after challenge, as described [11].
Briefly, single-cell preparations from spleen tissue were plated in
duplicate in 24-well plates (Nunc), at 56106 cells per mL. Cells
were incubated in RPMI 1640 medium (background control), or
separately stimulated with SLA (20 mg mL21), or individual phage
clones (161010 phages, each one), at 37uC in 5% CO2 for 48 h.
The IFN-c, IL-4, IL-10, IL-12, and GM-CSF levels were
determined in the culture supernatants, using commercial kits
(Pharmingen), according to manufacturer instructions. In order to
block IL-12, CD4, and CD8 mediated T cells cytokine release,
spleen cells of mice vaccinated and infected were in vitro
stimulated with SLA (20 mg mL21), and incubated in the presence
of 5 mg mL21 of monoclonal antibodies (mAb) against mouse IL-
12 (C017.8), CD4 (GK 1.5), or mouse CD8 (53–6.7). Appropriate
isotype-matched controls – rat IgG2a (R35-95) and rat IgG2b (95-
1) – were employed in the assays. Antibodies (no azide/low
endotoxin) were purchased from BD (Pharmingen).
Analysis of the humoral response
SLA-specific IgG1 and IgG2a antibodies were measured by
ELISA, as described elsewhere [11]. Briefly, previous titration
curves were performed to determine the most appropriate antigen
concentration and antibody dilution to be used. Falcon flexible
microtiter immunoassay plates (Becton Dickinson) were coated
with SLA (1.0 mg per well) in 100 mL coating buffer (50 mM
carbonate buffer) pH 9.6 for 18 h, at 4uC. After this, free binding
sites were blocked using 200 mL of TBS-T buffer containing 5%
casein for 1 h, at 37uC. After washing the plates 7 times using
TBS-T, they were incubated with 100 mL of individual sera for 1 h
at 37uC. Samples were diluted 1:100 in TBS-T containing 0.5%
casein solution. Plates were washed 7 times using TBS-T, and
incubated with the peroxidase-labeled antibodies specific to mouse
IgG1 or IgG2a isotypes (Sigma Aldrich) diluted at 1:5,000, and
incubated for 1 h at 37uC. After washing 7 times with TBS-T, the
reaction was developed through incubation with H2O2, orto-
phenylenediamine and citrate-phosphate buffer pH 5.0, for
30 min in the dark. The reaction was stopped by adding 25 mL
H2SO4 2 N, and optical density was read in an ELISA microplate
spectrophotometer, at 492 nm.
Statistical analysis
The statistical analysis was made using the GraphPad Prism
software (version 6.0 for Windows). Results were expressed by
mean 6 standard deviation (SD) of the groups. Outliers were
evaluated using ROUT test, and excluded from statistical analyses.
The normality analysis of the data was performed using the
D’Agostino & Pearson test. Statistical analysis of the results of
immunized and/or infected mice was performed by one-way
analysis of variance (ANOVA), using Tukey’s post-test for multiple
comparisons between the groups. Differences were considered
significant with P ,0.05. Data showed in this study are
representative of two independent experiments, which presented
similar results.
Results
Selection of the phage clones
First, the phage clones selection was performed by excluding
those that were recognized by antibodies present in sera samples of
healthy dogs. After, a positive selection process was performed, by
recovering the phage clones that were recognized by antibodies
present in the sera samples of dogs with asymptomatic and
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symptomatic VL. The technical protocol is summarized in the
Figure 1. Approximately 96 clones were randomly selected from
individual colonies, and their DNA sequences were amplified by
PCR and sequenced. Twenty clones had their sequences clearly
identified (Table 1), and an alignment showed that no identical
consensus motif could be detected between them (data not shown).
In addition, none of the 20 sequences selected were identified as
previously described sequences, or as non-specific binders to the
commons reagents used in the bio-panning cycles (data not
shown).
Spleen cells derived from naive or chronically infected with L.
infantum BALB/c mice were collected, pooled and separately
stimulated with each one of the 20 phage clones, at which time the
IFN-c and IL-4 levels were determined in the cultures superna-
tants. A wild-type phage clone, identical to the phage clones
present in the library, but that did not express foreign exogenous
mimotopes; a random non-specific to Leishmania phage clone
(NMSDFLRIQLRS), and non-stimulated cells (medium, back-
ground) were used as controls (Supplementary Figure). To select
the phage clones that presented the best results of immune
stimulation, their specificity and selectivity were calculated,
comparing the results obtained after the stimulation of spleen
cells with the values obtained from wild-type and non-relevant
phages. The specificity was defined as the ability of a clone to bind
to its target, based on the presence of mimotopes displayed on its
surface; whereas the selectivity was defined as the ability of a clone
to identify its cognate target in a mixture of different targets [41].
Initially, the specificity was calculated by dividing the IFN-c and
IL-4 values obtained of each evaluated individual clone by
respective values of these cytokines obtained after the wild-type
phage stimulus, using spleen cells derived from naive mice. Then,
with the corrected values, a ratio between IFN-c and IL-4 using
these new values was calculated, and the generated number was
defined as the specificity of clone. In the same way, the selectivity
was calculated by dividing the IFN-c and IL-4 values obtained of
each evaluated individual clone by respective values of these
cytokines obtained after the non-relevant phage stimulus, using
spleen cells derived from infected mice. Then, with the corrected
values, a ratio between IFN-c and IL-4 using these new values was
calculated, and the generated number was defined as the
selectivity of clone (Fig. 2). The phage clones that presented a
ratio $ 1.0 were selected, being this case observed with the B10
and C01 phages; in this context, these molecules were evaluated as
vaccine candidates against L. infantum infection.
Immunogenicity of the selected phage clones
The immunogenicity of B10 and C01 clones was evaluated in
BALB/c mice, four weeks after the last vaccine dose (Fig. 3). After
having undergone in vitro immune stimulation, spleen cells from
vaccinated mice significantly produced high levels of IFN-c and
IL-12 than did those secreted by spleen cells from all control
groups. No significant production of IL-4 and IL-10 could be
Figure 1. Schedule of technical protocol used in the bio-panning cycles of phage display.
doi:10.1371/journal.pone.0110014.g001
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observed in any experimental groups after stimulation with
individual clones (Fig. 3A). The ratios between IL-12/IL-4 and
IL-12/IL-10 (Fig. 3B), and between IFN-c/IL-4 and IFN-c/IL-10
(Fig. 3C) showed that vaccinated animals with B10/saponin or
C01/saponin presented an elevated Th1 immune response after
receiving a specific phage-stimulus. In addition, mice vaccinated
presented a humoral response with a higher predominance of
SLA-specific IgG2a isotype, in comparison to the IgG1 levels
(Fig. 3D).
Protective efficacy of the phage clones against
L. infantum
Next, this study analyzed whether the immunization with the
B10 or C01 clones plus saponin was in fact able to induce
protection against L. infantum. After the three vaccine doses, the
infection was performed and the animals were followed-up over a
10-weeks period, at which time the parasite burden in the liver,
spleen, dLN, and BM was determined. Significant reductions in
the number of parasites were observed in all of the evaluated
organs of the vaccinated mice, as compared to those that received
saline, or that were immunized with the wild-type phage clone plus
saponin (Fig. 4). Vaccinated mice with B10 or C01 clones plus
saponin, as compared to the saline group, as an infection control;
presented significant reductions in the parasite load in the liver
(2.5- and 5.3-log reductions, respectively; Fig. 4A), spleen (2.8- and
4.4-log reductions, respectively; Fig. 4B), dLN (2.5- and 4.0-log
reductions; respectively, Fig. 4C), and BM (2.5- and 5.3-log
reductions, respectively; Fig. 4D). In the same way, immunized
mice with B10 or C01 clones plus saponin, as compared to the
wild-type phage clone plus saponin group, as a phage control;
showed significant reductions in the parasite load in the liver (2.0-
and 4.2-log reductions, respectively), spleen (2.3- and 3.6-log
reductions, respectively), dLN (1.9- and 3.0-log reductions;
respectively), and BM (1.9- and 4.0-log reductions, respectively).
In both cases, the results showed an effective protection induced
by B10 and C01 phage clones against the Leishmania infection,
which could be represented by exposed mimotopes in their foreign
surface, mainly leading in count by their absence in the wild-type
phage clone.
Cellular response elicited after L. infantum infection
The production of cytokines in the supernatants of spleen cell
cultures stimulated with SLA, 10 weeks after infection, was
analyzed to evaluate the immunological correlates of protection
induced by previous immunization. The spleen cells derived from
mice vaccinated with B10 or C01 clones plus saponin produced
Table 1. Amino acid sequences from target peptides present
in the selected phage clones.
Clone Sequence
A10 LLSSKTL
B10 LSFPFPG
C01 FTSFSPY
C02 QATHFHS
D09 LASLPFR
E03 THVFSWI
E10 ACDPSPN
E11 TPSLHRS
F01 TAMARSA
F03 VALLPHH
F04 QSPPALL
F08 FSLLGSL
F09 VLLGPFP
F11 YPFSLLH
G02 SLGPQIK
G05 MSPTYLL
G09 DRAALSL
G11 ALTPQLL
G12 QTSPPLA
H05 FPLFGLS
doi:10.1371/journal.pone.0110014.t001
Figure 2. Evaluation of the selectivity and specificity of the selected phage clones. Spleen cells suspensions were obtained from naive or
chronically infected with L. infantum BALB/c mice. Cells were non-stimulated (medium; background control), or separately stimulated with each
phage clone, as well as the wild-type and non-relevant clones (161010 phages, each one) for 48 h at 37uC, 5% CO2. IFN-c and IL-4 levels were
measured in culture supernatants by capture ELISA. The black circles indicate the specificity of the phage clones, which was calculated by dividing
the IFN-c and IL-4 values obtained of each evaluated individual clone by respective values of these cytokines obtained after the wild-type phage
stimulus, using spleen cells derived from naive mice. With the corrected values, the ratio between IFN-c and IL-4 with these new values was
calculated, and the specificity of the each clone was defined. The white circles indicate the selectivity, which was calculated by dividing the IFN-c and
IL-4 values obtained of each evaluated individual clone by respective values of these cytokines obtained after the non-relevant phage stimulus, using
spleen cells derived from infected mice. With the corrected values, a ratio between IFN-c and IL-4 using these new values was calculated, and the
selectivity of each clone was defined.
doi:10.1371/journal.pone.0110014.g002
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higher levels of SLA-specific IFN-c, IL-12, and GM-CSF, than did
those secreted by spleen cells from control groups (Fig. 5A). In
contrast, the SLA-driven production of IL-4 and IL-10 showed
that vaccination with both phage clones induced no production of
these cytokines in the vaccinated and infected animals. In this
context, the ratios between IL-12/IL-4 and IL-12/IL-10 (Fig. 5B),
and between IFN-c/IL-4 and IFN-c/IL-10 (Fig. 5C), indicated
that vaccinated mice developed a Th1 response, which was
maintained after infection. It was also possible to observe that
vaccinated and infected mice presented a predominance of
SLA-specific IgG2a antibodies, which was significantly higher
than the IgG1 levels (Fig. 5D). The contribution of CD4+ and
CD8+ T cells, as well as the dependence of IL-12 production for
the SLA-specific IFN-c response from the spleen cells of mice
immunized with B10 or C01 phage clones plus saponin and
infected with L. infantum, was also evaluated (Fig. 6). The IFN-c
production was significantly suppressed using an anti-CD8+
monoclonal antibody in the spleen cell cultures. The addition of
anti-CD4+ or anti-IL-12 antibodies to the cultures also decreased
the production of this cytokine, as compared to the control cells
culture without treatment; however, the production of this
cytokine proved to be greater than that produced by the use of
the anti-CD8+ monoclonal antibody.
Discussion
In a recent study, our group developed a subtractive phage
display strategy that led to the identification of novel phage
antigens, represented by specific mimotopes, which were applied
to a sensitive and specific serodiagnosis of CVL [30]. In the
present study, phage display was applied to the identification of
antigens based on phage clones that could be evaluated in murine
models, such as vaccines against VL. The selected phages
expressing the target mimotopes were selected after bio-panning
cycles, which had been performed using a negative selection
process, employing sera samples from healthy dogs, as well as by a
positive selection process, based on the use of sera samples from
dogs with asymptomatic and symptomatic VL.
Figure 3. Cellular and humoral response induced in BALB/c mice by immunization with B10 or C01 phage clones plus saponin.
Single cells suspensions were obtained from the spleen of mice, four weeks after the last immunization. Cells were non-stimulated (medium;
background control), or separately stimulated with individual clones (161011 phages per mL, each one) for 48 h at 37uC, 5% CO2. IFN-c, IL-12, GM-
CSF, IL-4, and IL-10 levels were measured in culture supernatants by capture ELISA (A). Each bar represents the mean6 standard deviation (SD) of the
groups. Statistically significant differences in the IFN-c and IL-12 levels between the B10 or C01 clone plus saponin groups and control mice (saline,
saponin and wild-type phage plus saponin groups) were observed (***P ,0.0001). The ratio between IL-12/IL-10 and IL-12/IL-4 levels (B), and
between IFN-c/IL-10 and IFN-c/IL-4 levels (C) are also showed. Statistically significant differences in the ratios between the B10 or C01 clone plus
saponin groups and control groups were also observed (***P ,0.0001). The ratio between the Leishmania-specific IgG1 and IgG2a antibodies was
obtained from the different groups, and statistically significant differences between the B10 or C01 clone plus saponin and control groups were
observed (***P ,0.0001) (D).
doi:10.1371/journal.pone.0110014.g003
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It has been proposed that parasite antigens that are recognizable
by antibodies present in sera of dogs with asymptomatic VL may
be well-associated with a protective response, and could represent
potential vaccine candidates against leishmaniasis [42]. Here, the
selected phage clones were used for in vitro immune stimulation
experiments using spleen cells derived from naive or chronically
infected with L. infantum BALB/c mice. Two clones were selected
based on their ability of inducing a specific and selective higher
production of IFN-c, which was associated with low levels of IL-4.
These clones were then evaluated in BALB/c mice, according to
their ability to induce protection against L. infantum infection.
In the present study, spleen cells derived from naive or
chronically infected BALB/c mice were used in the selection of
the phage clones. Murine models have been used widely for the
development of vaccines against VL [20,43]. Studies employing
the mouse model have led to the characterization of the immune
mechanisms needed to develop organ specific immune responses,
which would clear the parasites from the liver, but not from the
spleen [43]. BALB/c mice infected with L. donovani or L. chagasi/
L. infantum are the most widely studied models of VL, but they
are also considered to be rather vulnerable, given that the infection
progresses during the first two weeks and become chronic. In the
murine VL, C57BL/6 mice mount an early Th1 immune
response, which prevents the further growth of the parasite, in
turn producing a self-healing phenotype [44], whereas susceptible
BALB/c mice mount early Th2 response, which results in a non-
healing lesion and an exaggeration of the disease [45]. In addition,
the respective resistance and susceptibility of C57BL/6 and
BALB/c strains depend not only on the Th1 and Th2 types of
immune responses from CD4+ T cells, but also on the genetic
background of the host [46]. In this manner, the immune
response, following the infection of inbred mouse strains with
viscerotropic Leishmania species, such as L. donovani and L.
infantum; can be considered to be similar to those observed in the
L. major mouse model. In this context, in the present study, spleen
cells derived from naive and chronically infected with a high
inoculums of L. infantum BALB/c mice were used to the in vitro
immune stimulation experiments, in order to select only the
candidate antigens able to subvert the undesirable Th2 profile in a
mouse strain highly susceptible to L. infantum infection.
Additional studies may well be carried out in order to extend
the observations present herein of the protective efficacy of the
B10 and C01 phage clones plus saponin vaccination to other mice
models and/or experimental conditions.
Phage display, since its first description [47] and introduction
into laboratory practice [48], has proven to be useful in selecting
antigens derived from phages, either using the phage clone itself or
the synthetic mimotopes, for vaccine development against diseases,
such as Burkitt’s lymphoma [49], melanoma [50], colorectal
cancer [51], hepatitis B virus [52], and rotavirus [53]; or against
Figure 4. Protection of BALB/c mice vaccinated with phage clones plus saponin against L. infantum. Mice inoculated with saline, saponin,
wild-type phage (WTP), B10 or C01 phage clones plus saponin were subcutaneously infected with 16107 stationary phase promastigotes of L.
infantum. The number of parasites in the liver (A), spleen (B), paws draining lymph nodes (C), and bone marrow (D) was measured, 10 weeks after
challenge by a limiting-dilution technique. Each bar represents the mean 6 standard deviation (SD) of the groups. Statistically significant differences
in the parasite load in all evaluated organs between the B10 and C01 clones plus saponin and control groups are showed (***P,0.0001). Data shown
are representative of two independent experiments, which presented similar results.
doi:10.1371/journal.pone.0110014.g004
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pathogens, such as Vibrio cholera [54], Candida albicans [55], and
Brugia malayi [56].
One could speculate that a major requirement for a successful
vaccine will be based not only on the most effective way of
inducing immunity, but also on the technical feasibility of its
production [57]. Phage-displayed peptides as candidates possess
two main advantages: first, peptides exposed in filamentous phages
are antigenic and immunogenic. As very potent carriers, phages
can be taken up and processed efficiently by mechanism of major
histocompatibility complex class I and II pathways [58,59].
Second, the amplification of phage is much simpler and
inexpensive than the conventional route of peptide synthesis or
production of recombinant proteins, besides of the final product is
composed by a high number of virion copies, reflecting in a high
exposition of the mimotopes to the immune system of the
immunized hosts. Also, phages can replicate inside the phagocityc
cells, and taken more time to be eliminated of the organism, in
comparison to use of synthetic peptides or recombinant proteins,
as well as they are not pathogenic to humans [60,61]. Other
important difference is based on that the immune stimulatory non-
methylated CpG motifs, present in the phage genome, can
contribute to the activation of the immune system of the mammal
hosts, through Toll-like receptors [62,63], reducing the necessity of
employ of immune adjuvants that are necessary to be incorporated
together to synthetic peptides and recombinant proteins.
On the other hand, some factors could be considered to
improve the protection observed in the present study using the
B10 and C01 phage clones. In this context, these phages were
screened from a Ph.D.-C7C Phage Display Peptide Library Kit,
which displayed peptides fused to the pIII protein of them. Minor
coat protein pIII is presented at five copies per virion, of which all
five can be fused to short peptides without interfering in the phage
infectivity. In contrast, major coat protein pVIII is presented at
2,700 copies per virion, of which 10% can be reliably fused to
peptides. As a result, peptides expressed as pIII fusions are present
at lower valency, whereas pVIII fusions are present at higher
valency [61]. Therefore, protection observed in this study could be
improved performing a construction of hybrid phage fusions of
B10 and C01 epitopes to the pVIII of the filamentous phages. In
addition, the incorporation of other protective epitopes could be
considered an efficient strategy to develop a more protective
Figure 5. Analysis of the cellular and humoral response in BALB/c mice after L. infantum challenge infection. BALB/c mice (n = 8, per
group) received saline or were immunized subcutaneously in their left hind footpad with 25 mg of saponin, and with B10, C01 or wild-type phage
clones (161011 phages, each one), associated with saponin. Three doses were administered at 2-week intervals, and four weeks after the last
immunization, the animals (n = 4) were infected subcutaneously in their right hind footpad with 16107 stationary promastigotes of L. infantum, and
were followed for 10 weeks. Single-cells suspensions were obtained from the spleens of mice in this time, and were non-stimulated (medium;
background control), or stimulated with SLA (20 mg mL21) for 48 h at 37uC, 5% CO2. Levels of IFN-c, IL-12, GM-CSF, IL-4 and IL-10 were measured in
culture supernatants by capture ELISA. Each bar represents the mean 6 standard deviation (SD) of the cytokines levels of the different groups (A).
Statistically significant differences between the B10 and C01 clones plus saponin and control groups (saline, saponin and wild-type phage plus
saponin groups) were observed (***P ,0.0001). The ratio between IL-12/IL-10 and IL-12/IL-4 levels (B), and between IFN-c/IL-10 and IFN-c/IL-4 levels
(C), are also showed. Statistically significant differences between the B10 and C01 clones plus saponin and control groups were observed (***P ,
0.0001). The ratio between SLA-specific IgG1 and IgG2a antibodies levels were calculated and statistically significant differences between the B10 and
C01 clones groups and the saline and saponin were also observed (*P ,0.005) (D).
doi:10.1371/journal.pone.0110014.g005
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phage-displayed multi-epitope based vaccine against Leishmania
infection.
Usually, in studies using the phage display technology applied to
select vaccine [64–66], or diagnosis [30,67] candidates to diseases;
the employed controls in the in vivo experiments are the own
phage molecules that not express the foreign peptides, namely as
wild-type phage. Normally, this control is derived of phage display
library used in the selection process. In the present study, the wild-
type phage used as a control was a filamentous phage derived from
Ph.D.-C7C Phage Display Peptide Library Kit, which did not
displayed exogenous peptides fused to the pIII protein, unlike to
the other clones employed in the selection. This fact could be
considered relevant, once the own phage particles present proteins
that can interact with the immune system of the hosts, leading to
the development of an immune response specific to them, and
interfering in the immune response specific to the target, in this
case, to the selected phage-displayed mimotopes. In consequence,
one could speculate that the higher or lower obtained protection in
the vaccination experiments could have been influenced by
molecules or parts of own phage, and did not due to the foreign
mimotopes selected in the bio-panning cycles.
In the murine VL, the production of IL-4 or IL-10 mediated
immune response inhibits the protective effects of the IFN-c
response, which may well be related to the deactivation of
macrophages and the onset of the disease in the infected animals
[68]. In studies evaluating vaccine candidates in the murine VL,
the immunogens are usually administered in mice associated with
Th1-type adjuvants and, after only a few weeks, they are infected
and followed-up for a couple of months. In this time, spleen cells
are collected and cultured in vitro with the antigens used in the
immunization process, and/or with Leishmania extracts, in order
to evaluate their immunogenicity. In this point, cytokines, such as
IFN-c and IL-12, markers of a Th1 response; and IL-4 and IL-10,
indicators of a Th2 response, have their levels determined and,
together with the results of the parasite burden, the efficacy of
immunogens is evaluated [10,15]. Thus, antigens capable of
stimulating the development of a Th1 response, as represented by
production of high levels of IFN-c in mice naive or chronically
infected with Leishmania, as opposite conditions, could be
considered promising candidates for use as a vaccine against
leishmaniasis.
Although the induction of a life-long protection against
reinfection, after recovering from a primary challenge, demon-
strates that a vaccine can be achieved, an effective candidate did
not exist. Some antigens, such as GP63, GP46, LACK, CPB,
CPA, A2, PSA-2, HASPB1, LeIF, and LCR1, have been tested
like recombinant proteins, synthetic peptides, and/or DNA
vaccines against leishmaniasis, but they have induced only partial
protection [69–71]. Recently, to solve this problem, the use of
remodeled live vaccines has become attractive, presenting notable
arguments concerning immunogenicity and efficacy [69,72,73].
The main disadvantage of such vaccines may well be based on the
difficulty of their large-scale production, as well as due to their
difficult standardization [70].
The present study described, for the first time, the employ of the
phage display technology to select antigens to be used as vaccines
against L. infantum, in a known murine model. The immunization
using B10 or C01 phage clones associated with saponin was able to
induce a specific Th1 response in vaccinated BALB/c mice, which
was characterized by an in vitro phages-specific production of
IFN-c, IL-12, and GM-CSF, combined with the presence of low
levels of IL-4 and IL-10; as well as a predominance of SLA-specific
IgG2a antibodies. After infection, immunized mice, as compared
to the controls, including phage (wild-type phage) and mimotope
(non-relevant phage) controls, displayed significant reductions in
the parasite burden in all evaluated organs, which was correlated
with a higher production of IFN-c by their spleen cells; one of the
main cytokines implicated in the protective immunity against
Leishmania [28,29,31].
As regards the profile of T cells involved on this production,
CD8+ T cells proved to be the major source of IFN-c in the
protected mice, since the depletion of these cells in the cultures of
spleen cells stimulated with SLA, significantly nullified this
response. Although previous reports have shown that the
activation of both CD4+ and CD8+ cells subsets may be important
for the killing of parasites in vaccinated mice using several parasite
recombinant antigens [15,32,33], the present study’s data suggest
that CD4+ cells may contribute to a lesser extent to the induction
of an IFN-c mediated response elicited by immunization using
B10 and C01 clones; being that the CD8+ T cells were the main
resource of IFN-c, and these cells could directly contribute to
infection control through their direct cytotoxic effect.
Figure 6. Involvement of IL-12, CD4+ and CD8+ T cells in the IFN-c production after L. infantum infection. Single-cells suspensions were
obtained from the spleens of mice that were immunized with B10 clone plus saponin (A) or C01 clone plus saponin (B), 10 weeks after L. infantum
infection. Levels of IFN-c were measured in culture supernatants by capture ELISA of spleen cells cultures stimulated with SLA (20 mg mL21) for 48 h
at 37uC, 5% CO2. Cultures were incubated in the absence (positive control) or in the presence of 5 mg mL
21 of monoclonal antibodies (mAb) against
mouse IL-12 (C017.8), CD4 (GK 1.5), or mouse CD8 (53-6.7). Statistically significant differences between non-treated control cells and cultures
incubated with anti-CD4, anti-CD-8 and anti-IL-12 monoclonal antibodies were observed (***P ,0.0001). Each bar represents the mean 6 standard
deviation (SD) of the IFN-c levels of the different groups.
doi:10.1371/journal.pone.0110014.g006
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The present study also demonstrates that the protection of
BALB/c mice was associated with a significant decrease in the
production of IL-4 and IL-10. Very low levels of parasite-specific
IL-10 were detected after the stimulation of spleen cells derived
from vaccinated mice, 10 weeks after infection. By contrast, spleen
cells from both control mice showed a significantly higher
production of this cytokine. Indeed, control of the parasite-
mediated IL-10 response may be critical for protection, since this
cytokine is considered to be the most important factor for VL
progression after infection with viscerotropic Leishmania species in
IL-10 deficient mice [74,75], or in mice treated with an anti-IL-10
receptor antibody [76]. In BALB/c mice, the IL-4-dependent
production of IgG1 antibodies is associated with disease progres-
sion into some Leishmania species, including L. amazonensis [77],
and L. infantum [78]. Here, immunized mice with the phage
clones presented higher levels of SLA-specific IgG2a antibodies, as
compared to IgG1 levels, also demonstrating the development of a
Th1 immune response in these animals.
Like observed to the IFN-c and IL-12 levels, spleen cells from
vaccinated mice, as compared to the control groups, produced
higher levels of clones-specific GM-CSF, a cytokine related to
macrophage activation and resistance in murine models against
intracellular pathogens, such as L. infantum [77], L. major [79],
and L. donovani [80]. It has also been reported that the
administration of a therapeutic vaccine containing Leishmania
antigens plus GM-CSF could be correlated with the curing of
Tegumentary leishmaniasis patients [81].
In conclusion, the present study describes a subtractive phage
display strategy that led to the identification of antigens to be
evaluated as vaccines against Leishmania infection. The results
indicated that two phage clones expressing target mimotopes
conferred protection in BALB/c mice against L. infantum.
Protection was correlated with CD4+ and, mainly, CD8+ T cells
response, which was characterized by high levels of IFN-c, IL-12,
and GM-CSF, associated with low levels of IL-4 and IL-10. The
data leads to the conclusion that the B10 and C01 phage clones
may well be effective vaccine candidates against VL. Studies are in
progress to identify and clone the native proteins that express these
mimotopes, in an attempt to compare their efficacy with those
found for mimotopes in the present study.
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